MARKET

AWH

AWH

Aspira Women`s Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.20
+0.28
+5.69%
Closed 16:00 05/07 EDT
OPEN
5.00
PREV CLOSE
4.920
HIGH
5.37
LOW
4.970
VOLUME
290.42K
TURNOVER
--
52 WEEK HIGH
10.54
52 WEEK LOW
1.870
MARKET CAP
582.12M
P/E (TTM)
-29.3785
1D
5D
1M
3M
1Y
5Y
Earnings Preview: Aspira (AWH) Q1 Earnings Expected to Decline
Zacks.com · 2d ago
Aspira Women’s Health Inc. to Report First Quarter 2021 Financial Results on May 13
AUSTIN, Texas, May 05, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that it will report financial results for the first quarter ended March 31, 2021 on Thursday, May 13, 2...
GlobeNewswire · 3d ago
Aspira Womens Health Stock Is Estimated To Be Significantly Overvalued
GuruFocus News · 04/24 07:12
Rugby-Scotland’s Wright out of Women’s Six Nations after red card
reuters.com · 04/06 18:52
A Look At The Fair Value Of Aspira Women's Health Inc. (NASDAQ:AWH)
In this article we are going to estimate the intrinsic value of Aspira Women's Health Inc. ( NASDAQ:AWH ) by projecting...
Simply Wall St. · 03/30 07:00
Aspira Inks Agreement For Ovarian Cancer Test; Shares Rise 32% Post-Market
Bioanalytical company Aspira Women’s Health has entered into an agreement with Dana-Farber Cancer Institute, Brigham and Women’s Hospital and Medical University Lodz to study their microRNA technology with Aspira’s solutions. Aspira Women’s Health (AWH) wi...
SmarterAnalyst · 03/26 14:38
BRIEF-Aspira Women's Health Reports Qtrly Loss Per Share of $0.06 (March 25)
reuters.com · 03/26 14:07
Aspira Womens Health Reports Fourth Quarter and Full Year 2020 Financial Results
Conference Call scheduled for today, March 25th at 4:30 p.m. ETAUSTIN, Texas, March 25, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today report...
GlobeNewswire · 03/25 21:20
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AWH. Analyze the recent business situations of Aspira Women`s Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AWH stock price target is 12.00 with a high estimate of 12.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 100
Institutional Holdings: 30.93M
% Owned: 27.63%
Shares Outstanding: 111.95M
TypeInstitutionsShares
Increased
39
1.31M
New
17
695.66K
Decreased
14
2.49M
Sold Out
3
192.12K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Independent Director
James LaFrance
President/Chief Executive Officer/Director
Valerie Palmieri
Chief Financial Officer
Robert Beechey
Independent Director
Sandra Brooks
Independent Director
Nancy Cocozza
Independent Director
Veronica Jordan
Independent Director
Nicole Sandford
Independent Director
David Schreiber
Declaration Date
Dividend Per Share
Ex-Div Date
05/22/2017
Dividend USD 0
07/07/2017
05/22/2017
Special Dividend USD 5
07/07/2017
About AWH
Aspira Women’s Health Inc., formerly Vermillion, Inc., is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells OVA1, Overa and OVA1PLUS risk of malignancy tests for ovarian cancer. The Company also sells a product for genetic testing for specific women’s health diseases, called ASPiRA GenetiX, with a core focus on ovarian cancer. OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor before planned surgery. The Overa is a second-generation biomarker panel intended to maintain its product’s sensitivity while improving specificity. OVA1PLUS is a service offering combining its OVA1 and Overa products, designed to enhance accuracy and reduce false elevations in the intermediate-risk area.

Webull offers kinds of Aspira Women's Health Inc stock information, including NASDAQ:AWH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AWH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AWH stock methods without spending real money on the virtual paper trading platform.